1. Home
  2. FNWB vs IMUX Comparison

FNWB vs IMUX Comparison

Compare FNWB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$10.26

Market Cap

96.3M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$10.35

Market Cap

155.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNWB
IMUX
Founded
1923
2016
Country
United States
United States
Employees
N/A
66
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.3M
155.8M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
FNWB
IMUX
Price
$10.26
$10.35
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$13.50
$36.00
AVG Volume (30 Days)
18.0K
252.4K
Earning Date
04-29-2026
05-14-2026
Dividend Yield
0.70%
N/A
EPS Growth
36.00
38.00
EPS
0.04
N/A
Revenue
$176,000.00
N/A
Revenue This Year
$19.24
N/A
Revenue Next Year
$8.90
N/A
P/E Ratio
$261.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.25
$0.51
52 Week High
$12.52
$17.43

Technical Indicators

Market Signals
Indicator
FNWB
IMUX
Relative Strength Index (RSI) 26.01 28.05
Support Level $9.55 $0.76
Resistance Level $10.38 $15.82
Average True Range (ATR) 0.26 1.04
MACD -0.08 -0.48
Stochastic Oscillator 11.02 2.38

Price Performance

Historical Comparison
FNWB
IMUX

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: